Illinois Municipal Retirement Fund decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 17.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,209 shares of the company’s stock after selling 1,900 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in IDEXX Laboratories were worth $4,809,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in IDXX. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $25,000. Elevation Wealth Partners LLC grew its position in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares during the period. Pension & Wealth Management Advisors Inc. purchased a new position in IDEXX Laboratories in the third quarter valued at $29,000. Arlington Trust Co LLC increased its holdings in IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after buying an additional 19 shares in the last quarter. Finally, Bell Investment Advisors Inc raised its position in shares of IDEXX Laboratories by 45.5% in the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.
Insider Activity
In related news, insider Jonathan Mazelsky sold 25,140 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total transaction of $17,678,196.60. Following the completion of the sale, the insider owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. This represents a 23.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Junius sold 1,200 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the sale, the director owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. The trade was a 33.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,428 shares of company stock valued at $28,567,934 in the last ninety days. 0.79% of the stock is currently owned by corporate insiders.
IDEXX Laboratories Price Performance
NASDAQ IDXX opened at $704.23 on Monday. The business has a fifty day moving average price of $562.41 and a 200 day moving average price of $573.52. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19. The company has a market cap of $55.48 billion, a P/E ratio of 47.49 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.22 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
IDXX has been the topic of several recent analyst reports. The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They set a “buy” rating and a $740.00 target price on the stock. UBS Group lifted their price target on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research note on Tuesday, November 3rd. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday, October 16th. Finally, Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $717.27.
Get Our Latest Stock Analysis on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Read More
- Five stocks we like better than IDEXX Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
